Soleno Therapeutics Announces 1-for-5 Reverse Stock Split
October 05, 2017 13:00 ET
|
Soleno Therapeutics
Previously approved reverse stock split to be implemented on Friday, October 6, 2017 REDWOOD CITY, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
September 25, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome
September 15, 2017 08:00 ET
|
Soleno Therapeutics
Updated Data Highlighted in Poster Presentation at 10th International Meeting of Pediatric Endocrinology Phase III Study Expected to Begin by End of 2017 REDWOOD CITY, Calif., Sept. 15, 2017 ...
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
September 13, 2017 08:00 ET
|
Soleno Therapeutics
Protection of Associated Claims into 2035 REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing...
Soleno Therapeutics Announces CFO Transition
September 05, 2017 16:58 ET
|
Soleno Therapeutics
David O’Toole to Depart Company; Interim CFO Appointed and Search for New CFO Initiated REDWOOD CITY, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 11, 2017 16:05 ET
|
Soleno Therapeutics
Completed Successful FDA Meeting for DCCR in Prader-Willi SyndromePreparing to begin Phase III program by the end of the yearMonetized Non-Strategic Assets Through Sale of NeoForce, Inc. Subsidiary ...
Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
July 24, 2017 16:05 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
July 05, 2017 08:00 ET
|
Soleno Therapeutics
Positive guidance received on key elements of Phase III programCompany expects to initiate pivotal Phase III clinical trial by year-end 2017DCCR has orphan designation for the treatment of PWS in the...
Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 11, 2017 16:05 ET
|
Capnia, Inc.
Completed merger with Essentialis, Inc. and concurrent financing of $10 millionNew company name, Soleno Therapeutics, Inc., to reflect new strategic focus on rare disease therapeutics; stock to trade...
Capnia Reports Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017 16:10 ET
|
Capnia, Inc.
REDWOOD CITY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today...